Perrigo Q3 2026 Financial Results - PERRIGO CO PLC

Financial Performance:

• Core net sales declined 1.7% YoY (sequential improvement from 8.3% in Q1 and 3.1% in Q2); organic core sales declined 1%.
• All-in net sales were $989 million, down 5.2% YoY, impacted by divestitures and infant formula sales decline of 9.6%.
• Core adjusted operating margin improved sequentially to 14.3% (up from 12.8% in Q1), while core gross margin declined 140 bps to 37.9% due to unfavorable mix and volume.
• Core adjusted EPS was $0.61 (down $0.06 YoY), boosted by a lower effective tax rate of 3.5% (up to 14% expected for full year).
• All-in adjusted diluted EPS was $0.60 (down $0.20 YoY), negatively impacted by $0.12 from infant formula planned under-absorption.
• Operating cash flow was $96 million (in line with expectations); capital expenditures were $18 million; $40 million returned to shareholders via dividends.
• Balance sheet: Cash and equivalents at $437 million; total debt at $3.3 billion; expected year-end net leverage of ~4x adjusted EBITDA.
• Operational Enhancement Program generated $42 million in savings YTD, on track for $60–$80 million in 2026.

Guidance and Future Outlook:

• Q4 and Full Year 2026 core outlook: Reported net sales decline 2.5–3.6%; organic decline 2.7–3.8%; adjusted operating margin 14–15%; diluted EPS $2.15–$2.35.
• Q4 and Full Year 2026 all-in outlook (excluding infant formula): Reported net sales decline 4.6–5.7%; adjusted operating margin 14.3–15.3%; diluted EPS $2.25–$2.45.
• Outlook assumes net interest expense of ~$162 million and an adjusted effective tax rate of ~14% for the full year.
• Full-year growth drivers remain dependent on innovation, distribution expansion, and demand generation, offset by headwinds from measured retailer inventory and European softness.
• Infant formula is reclassified as discontinued operations starting Q4 2026; all-in outlook now excludes this business entirely.

Business Segments and Product Lines:

• Self-care net sales declined 3.2%, driven by lower volumes in upper respiratory and pain/sleep; partially offset by growth in healthy lifestyle (nicotine replacement) and digestive health.
• Specialty care net sales declined 4.6%; Women's health grew (driven by LLM and Appeal brands), while Skin health faced declines from minoxidil and Maderma despite strong in-season performance for Compete and Jungle Formula.
• U.S. store brand OTC volume grew 2%, gaining 30 bps of market share; key brands (Compete, Appeal, LA1, Transfer Formula) demonstrated share gains and growth.
• European key brands achieved 6.5% value sales growth, gaining 80 bps of share.
• E-commerce volume represents 22% of U.S. volume (up from 13% in 2022); e-commerce category volume is up ~15% YoY, with Perigo holding a higher market share than the total market.
• Strategic focus includes innovation (e.g., GLP-1 activation for digestive health) and deeper retailer partnerships.

Market and Competitive Landscape:

• Perigo is the leader in U.S. store brand OTC and holds leading positions across key European brands.
• Consumption trends have strengthened sequentially in both U.S. and Europe, despite a challenging consumer environment.
• Retailer inventory positioning has become more measured ahead of the cough-and-cold season due to softer volumes in the previous two seasons.
• The company continues to gain market share in its core controlled categories and is expanding into e-commerce, a faster-growing channel.
• Oral care and Infant Formula business units are currently under strategic review for potential divestiture; infant formula has been sold.

Risks and Challenges:

• Headwinds include continued softness in the European consumer environment and more conservative retailer inventory buildup for the cough-and-cold season.
• Lower contract manufacturing volumes contributed a ~1 percentage point headwind to growth.
• Potential variability in seasonal illness incidence and shifting climate patterns affecting the timing of the cold/flu season.
• Upcoming normalization of tax rates in 2027 and removal of one-time tariff benefits will pressure margins.
• Inflationary pressures are expected to persist into 2027.
• Business complexity remains a primary internal challenge requiring simplification to drive consistent execution.

Management Commentary and Tone:

• Interim CEO Albert Manzoni expressed confidence in the company's portfolio and capabilities but acknowledged that "complexity" has historically hindered consistent results.
• Management emphasized a decisive shift toward simplifying the business, focusing only on areas with the "greatest right to win."
• The tone is optimistic regarding the effectiveness of the "3S" (Stabilize, Streamline, Strengthen) plan, citing sequential improvements in margins and share gains.
• Management reaffirmed commitment to capital discipline, with a focus on debt reduction and aligned capital allocation following the infant formula divestiture.
• Confidence is high that the simplified portfolio will allow Perigo to exit 2026 as a stronger, more focused self-care company.

Analyst Questions and Answers:

• Strategy & Divestitures: Analyst confirmed interest in the status of the oral care review; Management confirmed oral care and infant formula are the two assets under review for sale to simplify the company.
• Market Share Details: Management detailed that share gains are broad-based in the U.S. and Europe, excluding specific categories like oral electrolytes and skin health (due to single brand issues), while highlighting new co-innovation opportunities with retailers.
• 2027 Outlook & Tariffs: Management noted 2027 will see margin improvement from absorption recovery and divestitures, offset by tariff benefit normalization, tax rate normalization, and inflation. Tariff benefits in Q3 were approximately $4.5 million.
• Inventory & Replenishment: Regarding retailer inventory, management clarified that retailers did not over-stock for the season as historically anticipated; replenishment demand is expected if the illness season intensifies, potentially impacting Q4 or Q1 2027.
• Cash Flow & CapEx: The infant formula divestiture is expected to significantly reduce capital expenditure requirements, allowing capital to be redirected toward core OTC growth opportunities.

Other Key Points:

• The company is actively shifting its portfolio toward faster-growing segments, such as digestive health support for GLP-1 consumers.
• E-commerce is identified as a key competitive advantage, with share significantly higher than the total market average.
• Management is committed to a quarterly review of dividend policy to ensure capital allocation remains aligned with the simplified strategy.
• The "3S" plan is cited as the primary driver for sequential improvement, with specific focus on stabilizing operations, streamlining the portfolio, and strengthening growth drivers.